Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ketamine in the Acute Phase of Suicidal Ideation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* French speaking patients freely hospitalized for prevention of suicide and who have a medium or high suicide risk score according to a MINI structured interview~* The patient is able to understand how the study is carried out and the tests performed~* The patient is deemed capable of giving his/her informed consent~* The patient has been correctly informed~* The patient must have given his/her informed and signed consent.~* The patient must be insured or beneficiary of a health insurance plan.~* Presence of suicidal ideation according to the SSI score (score \> 3)~* Negative pregnancy test for women of childbearing age~Exclusion Criteria:~* The patient is participating in another interventional study~* Within the past three months, the patient has participated in another interventional study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection~* The patient is an adult under guardianship~* The patient refuses to sign the consent~* The patient is not able to understand the informed consent~* Pregnancy or breastfeeding~* History of schizophrenia or other psychotic disorders~* Presence of psychotic symptoms at initial interview~* Schizoid or schizotypic personality disorder~* Positive urine screening for illicit substances, excluding cannabis~* Substance dependence in the preceding month (excluding nicotine or caffeine)~* Concomitant treatment with electroconvulsive therapy~* Unstable somatic pathology~* Clinically significant anomalies found during clinical examination, biological test or ECG~* Non-stabilized hypertension or hypertension \> 180/100~* Known or suspected contra-indication for ketamine (includes interactions): hypersensitivity to ketamine, hypertension, class IV cardiac insufficiency, history of stroke, hepatic or cutaneous porphyria, history of intracranial hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Patients randomized to this group will be treated via Ketamine infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of ketamine Intervention: Follow-up between perfusions Intervention: 2nd perfusion of ketamine Intervention: Follow-up after perfusions
- Placebo/Control (Type: PLACEBO_COMPARATOR): Patients randomized to this group will be treated via saline solution infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of saline Intervention: Follow-up between perfusions Intervention: 2nd perfusion of saline Intervention: Follow-up after perfusions

Based on this trial design, predict the completion outcome and termination type (if applicable).